Behavioural deterioration induced by intrahippocampal NAC 61-95 injections and attenuation with ibuprofen

Behavioural Brain Research

Volumn 208, Issue 1, 2010, Pages 274-277

  O'Hare, Eugene ^a   Elliott, Jennifer J ^a   Hobson, Peter ^b   Spanswick, David ^c   Kim, Eun Mee ^d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF WARWICK   (United Kingdom)

^d UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Dementia; Inflammation; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; IBUPROFEN; SUCROSE; ALPHA SYNUCLEIN (61 95); ALPHA-SYNUCLEIN (61-95); NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; CELL COUNT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; INSTRUMENTAL CONDITIONING; MALE; NERVE CELL STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; TREATMENT RESPONSE; ANIMAL; ANIMAL BEHAVIOR; CHEMICALLY INDUCED DISORDER; MENTAL DISEASE; PATHOLOGY; REINFORCEMENT; SPRAGUE DAWLEY RAT;

ALPHA-SYNUCLEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BEHAVIOR, ANIMAL; CA3 REGION, HIPPOCAMPAL; CONDITIONING, OPERANT; IBUPROFEN; MALE; MENTAL DISORDERS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT SCHEDULE;

EID: 77951931376     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.11.027     Document Type: Article

References (25)

1. Bodles A.M., Guthrie D.J.S., Greer B., Irvine G.B. Identification of the regions of non-Aβ component (NAC) of Alzheimer's disease amyloid responsible of its aggregation and toxicity. J Neurochem 2001, 7:384-395.
2. Buter T.C., van den Hout A., Mattews F.E., Larsen J.P., Brayne C., Aarsland D. Dementia and survival in Parkinson's disease: a 12 year population study. Neurology 2008, 70:1017-1022.
3. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson's disease. Arch Neurol 2003, 60:1059-1064.
4. Cummings J.L. Intellectual impairment in Parkinson's disease: clinical, pathologic and biochemical correlates. J Geriat Psychiat Neurol 1988, 1:24-36.
5. El-Agnaf O.M., Salem S.A., Paleologou K.E., Curran M.D., Gibson M.J., Court J.A., et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006, 20:419-425.
6. El-Agnaf O.M., Salem S.A., Paleologou K.E., Cooper L.J., Fullwood N.J., Gibson M.J., et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 2003, 17:1945-1947.
7. El-Agnaf O.M., Bodles A.M., Guthrie D.J.S., Harriott P., Irvine G.B. The N-terminal region of non Aβ-component of Alzheimer's disease amyloid is responsible for its tendency to assume beta-sheet and aggregate to form fibrils. Eur J Biochem 1998, 15:157-163.
8. Hirohata M., Ono K., Morinaga A., Yamada M. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. Neuropharmacology 2008, 54:620-627.
9. Hobson J.P., Meara R.J. The risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the UK. Mov Dis 2004, 19:1043-1049.
10. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurol 2000, 54:1916-1921.
11. 61-95 injections in the rat and attenuation with vitamin E. Prog Neuro-Psychopharm Biol Psych 2009, 33:945-951.
12. Lee S.-J. Origins and effects of extracellular α-synuclein: implications in Parkinson's disease. J Mol Neurosci 2008, 34:17-22.
13. Lee H.J., Patel S., Lee S.J. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005, 25:6016-6024.
14. Litvan I., Mohre E., Williams J., Gomez C., Chace T.N. Differential memory and executive functions in demented patients with Parkinson's disease and Alzheimer's disease. J Neurol Neurosurg Psych 1991, 54:25-29.
15. Maroteaux L., Scheller R.H. The rat-brain synuclein-family of proteins transiently associated with neuronal membrane. Mol Brain Res 1991, 11:335-343.
16. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurol 1988, 38:1285-1291.
17. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
18. Richardson R.L., Kim E.-M., Shephard R.A., Gardiner T., Cleary J., O'Hare E. Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Abeta(1-42) injections in the rat. Brain Res 2002, 954:1-10.
19. Shimohama S., Sawada H., Kitamura Y., Taniguchi T. Disease model: Parkinson's disease. Trends Mol Med 2003, 9:360-365.
20. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goebert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998, 95:6469-6473.
21. Sung J.Y., Kim J., Paik S.R., Park J.H., Ahn Y.S., Chung K.C. Induction of neuronal cell death by Rab5A-dependent endocytosis of alpha-synuclein. J Biol Chem 2001, 276:27441-27448.
22. Treves A., Rolls E.T. Computational analysis of the role of the hippocampus in memory. Hippocampus 2004, 4:374-391.
23. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 1993, 90:11282-11286.
24. Weldon D.T., O'Hare E., Kuskowski M.A., Cleary J., Mach J. Alternating-lever cyclic-ratio schedule analysis of the effects of atropine sulphate. Pharmacol Biochem Behav 1996, 54:753-757.
25. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., et al. Aggregated a-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005, 19:533-554.